ImmuCell Q4 Earnings Call Highlights [Yahoo! Finance]
ImmuCell Corporation (ICCC)
US:NASDAQ Investor Relations:
immucell.com/investors
Company Research
Source: Yahoo! Finance
subclinical mastitis program, taking a roughly $2.7M non-cash impairment on Re-Tain-related assets. Full-year product sales rose 4.3% to $27.6M and gross margin expanded to (from 30% in 2024), helping cut the net loss to about $1.0M (-$0.12/share) and deliver $1.6M of operating income, although Q4 margins were partly pressured by ~$650K of inventory write-downs. Management increased manufacturing capacity to 4.6M units in 2025 and believes 5–6M units are achievable with operational improvements, plans to repurpose Re-Tain assets for First Defense, and is expanding the commercial team; year-end cash was $3.8M with $13.0M in working capital. Interested in ImmuCell Corporation? Here are five stocks we like better. ImmuCell (NASDAQ:ICCC) executives used the company's fourth-quarter and full-year 2025 earnings call to highlight a year of operational change, improved margins, and a strategic pivot toward expanding its First Defense calf scours prevention franchise while stepping awa
Show less
Read more
Impact Snapshot
Event Time:
ICCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ICCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ICCC alerts
High impacting ImmuCell Corporation news events
Weekly update
A roundup of the hottest topics
ICCC
News
- ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025 [Yahoo! Finance]Yahoo! Finance
- ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025GlobeNewswire
- ImmuCell (ICCC) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d+)" to "hold (c-)".MarketBeat
- ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025 [Yahoo! Finance]Yahoo! Finance
- ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025GlobeNewswire
ICCC
Sec Filings
- 3/4/26 - Form 8-K
- 2/9/26 - Form 8-K
- 2/2/26 - Form 8-K
- ICCC's page on the SEC website